Comparison of the Relative Sensitivity of Clinical, Endoscopic, and Histologic Remission for Detection of Treatment Efficacy in Ulcerative Colitis Trials

Rocio Sedano; Malcolm Hogan; Guangyong Zou; Neeraj Narula; Siddharth Singh; Christopher Ma; Brian G Feagan; Vipul Jairath

doi:10.1093/ibd/izac128

Comparison of the Relative Sensitivity of Clinical, Endoscopic, and Histologic Remission for Detection of Treatment Efficacy in Ulcerative Colitis Trials

Inflamm Bowel Dis. 2023 Feb 1;29(2):324-327. doi: 10.1093/ibd/izac128.

Authors

Rocio Sedano^{1

2}, Malcolm Hogan², Guangyong Zou², Neeraj Narula³, Siddharth Singh⁴, Christopher Ma^{2

5

6}, Brian G Feagan^{1

2

7}, Vipul Jairath^{1

2

7}

Affiliations

¹ Division of Gastroenterology, Department of Medicine, Western University, London, Ontario, Canada.
² Alimentiv, Inc., London, Ontario, Canada.
³ Division of Gastroenterology, Department of Medicine, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
⁴ Division of Gastroenterology, University of California San Diego, La Jolla, California, USA.
⁵ Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
⁶ Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
⁷ Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.

PMID: 35749316
DOI: 10.1093/ibd/izac128

No abstract available

Keywords: clinical trials; outcome sensitivity; remission; treatment efficacy; ulcerative colitis.

Plain language summary

This systemic review and quantitative analysis of placebo-controlled ulcerative colitis (UC) induction trials found higher pooled histologic remission rates compared with clinical and endoscopic remission rates at the same timepoint, and no significant differences in pooled relative risks for these outcomes between treatment groups; supporting the concept that histologic remission is not less sensitive than clinical or endoscopic remission.

MeSH terms

Colitis, Ulcerative* / drug therapy
Humans
Mesalamine / therapeutic use
Remission Induction
Sulfasalazine / therapeutic use
Treatment Outcome

Substances

Mesalamine
Sulfasalazine